Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 2, 1997, Pages 636-647

  Patel, Smita ^a   Freedman, Stephen ^a   Chapman, Kerry L ^a   Emms, Frances ^a   Fletcher, Alan E ^a   Knowles, Mick ^a   Marwood, Rosemarie ^a   Mcallister, George ^a   Myers, Jan ^a   Patel, Shil ^a   Curtis, Neil ^a   Kulagowski, Jan J ^a   Leeson, Paul D ^a   Ridgill, Mark ^a   Graham, Mike ^a   Matheson, Steve ^a   Rathbone, Denise ^a   Watt, Alan P ^a   Bristow, Linda J ^a   Rupniak, Nadia M J ^a   Baskin, Elizabeth ^a,b   Lynch, Joseph J ^a,b   Ragan, C Ian ^a   more..

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; ADENYLATE CYCLASE; CLOZAPINE; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOPAMINE RECEPTOR BLOCKING; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SQUIRREL MONKEY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; CHO CELLS; CRICETINAE; CYCLIC AMP; DOPAMINE; DOPAMINE ANTAGONISTS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MALE; MICE; PHENAZOCINE; PROLACTIN; PYRIDINES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; SAIMIRI;

EID: 9844254480     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. BALDESSARINI, R. J. AND FRANKENBURG, F. R.: Clozapine: A novel antipsychotic agent. N. Engl. J. Med. 324: 746-754, 1991.
2. BALDESSARINI, R. J. AND TARSY, D.: Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs. Ann. Rev. Neurosci. 3: 23-41, 1980.
3. BASKIN, E. P., SERIK, C. M., WALLACE, A. A., BROOKES, L. M., SELNICK, H. G., CLAREMON, D. A., LYNCH, J. J.: Effects of new and potent methanesulfonanilide Class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle. J. Cardiovasc. Pharmacol. 18: 406-414, 1991.
4. 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci. 35: 1885-1893, 1984.
5. BRISTOW, L. J., HUTSON, P., THORN, L. AND TRICKLEBANK, M. D.: The glycine/ NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents. Br. J. Pharmacol. 108: 1156-1163, 1993.
6. 4 receptor antagonist, L-745,870 on amphetamine-induced behaviours in rodents. Br. J. Pharmacol. 119: 210P, 1996.
7. CATTERALL, W. A., MORROW, C. S., DALY, J. W. AND BROWN, G. B.: Binding of batrachotoxin A 20-α-benzoate to a receptor site associated with sodium channels in synaptic nerve ending particles. J. Biol. Chem. 256: 8922-8927, 1981.
8. 50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3018, 1973.
9. CREESE, I., BURT, D. R. AND SNYDER, S. H.: Biochemical actions of neuroleptic drugs: focus on dopamine receptor. In Handbook of Pharmacology, vol. 10, ed. by L. L. Iversen, S. D. Iversen and S. H. Snyder, pp. 37-89, New York, Plenum, 1978.
10. CULLEN, B. R.: Use of eukaryotic expression technology in the functional analysis of cloned genes. Methods Enzymol. 152: 684-704, 1987.
11. CUNNINGHAM OWENS, D. G.: Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs 51: 895-930, 1996.
12. FITTON, A. AND HEEL, R. C.: Clozapine: A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40: 722-747, 1990.
13. KAROUM, F. AND EGAN, M. F.: Dopamine release and metabolism in rat frontal cortex, nucleus accumbens and striatum: A comparison of acute clozapine and haloperidol. Brit. J. Pharmacol. 105: 703-707, 1992.
14. KRAMER, M., LAST, B., ZIMBROFF, D., HAFEZ, H., ALPERT, M., ALLAN, E., ROTROSEN, J., McEVOY, J., KANE, J., KRONIG, M., MERIDETH, C., SILVA, J. A., ERESHEFSKY, L., MARDER, S., WIRSHING, W., CONLEY, R., GETSON, A., CHAVEZ-ENG, C., CHENG, H. ANS REINES, S.: The effects of a selective D4 receptor antagonist (L-745,870) in acutely psychotic schizophrenic patients. Arch. Gen. Psychiatry 54: 567-572, 1997.
15. KULAGOWSKI, J. J., BROUGHTON, H. B., CURTIS, N. R., MAWER, I. M., RIDGILL, M. P., BAKER, R., EMMS, F., FREEDMAN, S. B., MARWOOD, R. M., PATEL, S., PATEL, S., RAGAN, C. I. AND LEESON, P.: D. 3-[[4-(4-Chlorophenyl)piperazin-1-yl]-methyl]-1H-pyrrolo[2,3-b]pyridine: An antagonist with high affinity and selectivity for the human dopamine D4 receptor. J. Med. Chem. 39: 1941-1942, 1996.
16. LAHTI, R. A., EVANS, D. L., STRATMAN, N. C. AND FIGUR, L. M.: Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur. J. Pharmacol. 236: 483-486, 1993.
17. LAZARENO, S., FARRIES, T. AND BIRDSALL, N. J. M.: Pharmacological characterisation of guanine nucleotide exchange reactions in membranes from CHO cells stably transfected with human muscarinic receptors M1-M4. Life Sci. 52: 449-456, 1993.
18. LEATHERBARROW, R. J.: GraFit Version 3.0, Erithacus Software Ltd., Staines, U. K. 1992.
19. McALLISTER, G., KNOWLES., M. R., WARD-BOOTH, S. M., SINCLAIR, H. A., PATEL, S., MARWOOD, R., EMMS, F., PATEL, S., SMITH, A., SEABROOK, G. R. AND FREEDMAN, S. B.: Functional coupling of human D2, D3 and D4 dopamine receptors in HEK293 cells. J. Recept. Signal Transduct. Res. 15: 267-281, 1995.
20. MELTZER, H. Y., GOODE, D. J. AND FAND, V. S.: The effect of psychotropic drugs on endocrine function. In Psychopharmacology: A Generation of Progress, ed. by M. A., Lipton, A. DiMascio and K. F. Killam, pp. 509-529. New York, Raven. 1978.
21. MELTZER, H. Y., KOENIG, J. I., NASH, J. F. AND GUDELSKY, G. A.: Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs. Acta Psychiatr. Scand. Suppl. 352: 24-29, 1989.
22. + exchange assessed by quantification of extracellular acidification. J. Biol. Chem. 36: 25748-25753, 1992.
23. PATEL, S., PATEL, S., MARWOOD, R. M., FLETCHER, A. E., KULAGOWSKI, J. J., RAGAN, C. I., LEESON, P. D. AND FREEDMAN, S. B.: L-745,870 (3-{[4-(4-chlorophenyl) piperazin-1-yl] methyl} -1H-pyrollo [2,3-b] pyridine: A high affinity and selective dopamine D4 receptor antagonist. Br. J. Pharmacol. 119: 30P, 1996.
24. 125I] L-750,667, a novel radioligand for the dopamine D4 receptor. Mol. Pharmacol. 50: 1658-1664, 1996a.
25. RALEY-SUSMAN, K. M., MILLER, K. R., OWICKI, J. C. AND SAPOLSKY, R. M.: Effects of excitotoxin exposure on metabolic rate of of primary hippocampal cultures: application of silicon microphysiometry to neurobilogogy. J. Neurosci. 12: 773-780, 1992.
26. 3H] Desmethoxyverapamil labels multiple calcium channel modulator receptors in brain and skeletal muscle membranes: Differentiation by temperature and dihydropyridines. J. Pharmacol. Exp. Ther. 237: 731-738, 1986.
27. SEEMAN, P.: Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacol. 7: 261-284, 1992.
28. SEEMAN, P. AND VAN TOL, H. H. M.: Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15: 264-270, 1994.
29. VAN TOL, H. H. M., BUNZOW, J. R., GUAN, H.-C., SUNAHARA, R. K., SEEMAN, P., NIZNIK, H. B. AND CIVELLI, O.: Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614, 1990.